BMS-3

• Description :

  BMS-3 is a potent LIMK inhibitor with IC50s of 5 nM and 6 nM for LIMK1 and LIMK2, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  LIM Kinase (LIMK)

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/BMS-3.html

• Purity :

  99.89

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(C1CC1)NC2=NC=C(C3=CC(C(F)F)=NN3C4=C(Cl)C=CC=C4Cl)S2

• Molecular Formula :

  C17H12Cl2F2N4OS

• Molecular Weight :

  429.27

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ross-Macdonald P, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther. 2008 Nov;7 (11) :3490-8.|[2]Romarowski A, et al. PKA-dependent phosphorylation of LIMK1 and Cofilin is essential for mouse sperm acrosomal exocytosis. Dev Biol. 2015 Sep 15;405 (2) :237-49.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  LIMK1; LIMK2

• CAS Number :

  [1338247-30-5]